Verily moves further into heart research as Study Watch picks up new FDA clearance

Fierce Healthcare January 24, 2020
Heather Landi

Verily is looking to build solutions to help with screening, diagnosis, and management of patients with atrial fibrillation (AFib).

Alphabet’s life sciences research arm Verily received FDA 510(k) clearance for its Study Watch to offer an irregular pulse monitor feature.

Verily plans to leverage this new capability to detect irregular heart rate to build solutions to help with screening, diagnosis, and management of patients with atrial fibrillation (AFib), the most prevalent irregular heartbeat, William Marks, M.D., head of clinical science at Verily, wrote in a blog post.

“This validates our approach at Verily to building robust, clinical-grade tools and solutions that can support clinicians in delivering the highest level of care and improve self-management for patients,” Marks wrote.

A year...

Today's Sponsors

Today's Sponsor